# A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

> **NCT02386111** · PHASE1 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 17 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Kidney Diseases
- Kidney Neoplasms
- Urogenital Neoplasms
- Urologic Diseases
- Urologic Neoplasms
- Neoplasms
- Neoplasms by Histologic Type
- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Combination of varlilumab and sunitinib

## Key facts

- **NCT ID:** NCT02386111
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2017-08
- **Final completion:** 2017-11-03
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Portfolio re-prioritization
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386111, "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02386111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*